NO-donating aspirin induces phase II enzymes in vitro and in vivo

Carcinogenesis

Volumn 27, Issue 4, 2006, Pages 803-810

  Gao, Jianjun ^b   Kashfi, Khosrow ^a   Liu, Xiaoping ^b   Rigas, Basil ^b  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SCAVENGER; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CELL STRAIN HT29; CHEMOPROPHYLAXIS; COLON ADENOCARCINOMA; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOMA; MICROELECTRODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

ADENOCARCINOMA; ANIMALS; ASPIRIN; CHEMOPREVENTION; COLONIC NEOPLASMS; ENZYME INDUCTION; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; NITRIC OXIDE; PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33645280058     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi262     Document Type: Article

References (38)

1. Rigas,B. and Kashfi,K. (2004) Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med., 10, 324-330.
2. Kashfi,K., Ryan,Y., Qiao,L.L., Williams,J.L., Chen,J., Del Soldato,P., Traganos,F. and Rigas,B. (2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther., 303, 1273-1282.
3. Bak,A.W., McKnight,W., Li,P., Del Soldato,P., Calignano,A., Cirino,G. and Wallace,J.L. (1998) Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sciences, 62, L367-L373.
4. Williams,J.L., Kashfi,K., Ouyang,N., del Soldato,P., Kopelovich,L. and Rigas,B. (2004) NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem. Biophys. Res. Commun., 313, 784-788.
5. Fiorucci,S., Santucci,L., Gresele,P., Faccino,R.M., Del Soldato,P. and Morelli,A. (2003) Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic study. Gastroenterology, 124, 600-607.
6. Iconomou,G., Kalofonos,H.P., Koutras, A.K., Vagenakis,A.G., Rigas,B. and (2005) A pilot study of no-donating aspirin in patients with pancreatic cancer pain. J. Support Oncol., in press.
7. Nath,N., Kashfi,K., Chen,J. and Rigas,B. (2003) Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc. Natl Acad. Sci. USA, 100, 12584-12589.
8. Williams,J.L., Nath,N., Chen,J., Hundley,T.R., Gao,J., Kopelovich,L., Kashfi,K. and Rigas,B. (2003) Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: Implications for chemoprevention. Cancer Res., 63, 7613-7618.
9. Spiegel,A., Hundley,T.R., Chen,J., Gao,J., Ouyang,N., Liu,X., Go,M.F., Tsioulias,G.J., Kashfi,K. and Rigas,B. (2005) NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem. Pharmacol., 70, 993-1000.
10. Hundley,T.R. and Rigas,B. (2005) NO-donating aspirin inhibits colon cancer cell growth via MAP kinase activation. J. Pharmacol. Exp. Ther., [Epub ahead of print] PMID: 16169935., In press.
11. Wilkinson,J.T. and Clapper,M.L. (1997) Detoxication enzymes and chemoprevention. Proc. Soc. Exp. Biol. Med., 216, 192-200.
12. Kong,A.N., Owuor,E., Yu,R., Hebbar,V., Chen,C., Hu,R. and Mandlekar,S. (2001) Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab. Rev., 33, 255-271.
13. Grubben,M.J., Nagengast,F.M., Katan,M.B. and Peters,W.H. (2001) The glutathione biotransformation system and colorectal cancer risk in humans. Scand J. Gastroenterol. Suppl., 68-76.
14. Sheweita,S.A. and Tilmisany,A.K. (2003) Cancer and phase II drug-metabolizing enzymes. Curr. Drug Metab., 4, 45-58.
15. Kwak,M.K., Wakabayashi,N. and Kensler,T.W. (2004) Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat. Res., 555, 133-48.
16. Lee,J.S. and Surh,Y.J. (2005) Nrf2 as a novel molecular target for chemoprevention. Cancer Lett., 224, 171-84.
17. Morimitsu,Y., Nakagawa,Y., Hayashi,K. et al. (2002) A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway. J. Biol. Chem., 277, 3456-63.
18. Johnson,D. and Lardy,H. (1958) Substrate-selective inhibition of mitochondrial oxidations by enhanced tonicity. Nature, 181, 701-702.
19. Gamble,M.S. and Cook,G.A. (1985) Alteration of the apparent Ki of carnitine palmitoyltransferase for malonyl-CoA by the diabetic state and reversal by insulin. J. Biol. Chem., 260, 9516-9519.
20. Park,B.C., Liu,Y., Averill,D.R. Jr, Jackman,M.-I. and Rosenberg,D.W. (1995) Cytochemical localization of the acetone-inducible cytochrome P-450 isoform, CYP2E1, in murine colonic epithelium. Pharmacology, 50, 339-347.
21. Kashfi,K., McDougall,C.J. and Dannenberg,A.J. (1995) Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human. Clin. Pharmacol. Ther., 58, 625-630.
22. Prochaska,H.J. and Santamaria,A.B. (1988) Direct measurement of NAD(P)H:qUinone reductase from cells cultured in micAotiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal. Biochem., 169, 328-336.
23. Habig,W.H., Pabst,M.J. and Jakoby,W.B. (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem., 249, 7130-7139.
24. Richie,J.P. Jr, Skowronski,L., Abraham,P. and Leutzinger,Y. (1996) Blood glutathione concentrations in a large-scale human study. Clin. Chem., 42, 64-70.
25. Prochaska,H.J., Santamaria,A.B. and Talalay,P. (1992) Rapid detection of inducers of enzymes that protect against carcinogens. Proc. Natl Acad. Sci. USA, 89, 2394-2398.
26. Beaumont,P.O., Moore,M.J., Ahmad,K., Payne,M.M., Lee,C. and Riddick,D.S. (1998) Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin. Cancer Res., 58, 947-955.
27. O'Dwyer,P.J., Yao,K.S., Ford,P., Godwin,A.K. and Clayton,M. (1994) Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. Cancer Res., 54, 3082-3087.
28. Meister,A. (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther., 51, 155-194.
29. Dhakshinamoorthy,S. and Porter,A.G. (2004) Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. J. Biol. Chem., 279, 20096-20107.
30. Hess,D.T., Matsumoto,A., Kim,S.O., Marshall,H.E. and Stamler,J.S. (2005) Protein S-nitrosylation: Purview and parameters. Nat. Rev. Mol. Cell. Biol., 6, 150-166.
31. Rayyan,Y., Williams,J. and Rigas,B. (2002) The role of NSAIDs in the prevention of colon cancer. Cancer Invest., 20, 1002-1011.
32. Tew,K.D., O'Brien,M., Laing,N.M. and Shen,H. (1998) Coordinate changes in expression of protective genes in drug-resistant cells. Chem. Biol. Interact., 111-112, 199-211.
33. Smitskamp-Wilms,E., Hendriks,H.R. and Peters,G.J. (1996) Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Gen. Pharmacol., 27, 421-429.
34. Begleiter,A., Leith,M.K., Curphey,T.J. and Doherty,G.P. (1997) Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncol. Res., 9, 371-382.
35. Winski,S.L., Hargreaves,R.H., Butler,J. and Ross,D. (1998) A new screening system for NAD(P)H:qUinone oxidoreductase (NQO1)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin. Cancer Res., 4, 3083-3088.
36. Kitamura,S., Terada,A., Kamio,H., Sugihara,K., Koga,N. and Ohta,S. (1999) DT-diaphorase-like quinone reductase in rat plasma. Biol. Pharm. Bull., 22, 883-885.
37. Kashfi,K., Borgo,S., Williams,J.L., Chen,J., Gao,J., Glekas,A., Benedini,F., Del Soldato,P. and Rigas,B. (2005) Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J. Pharmacol. Exp. Ther., 312, 978-988.
38. Gao,J., Kashfi,K. and Rigas,B. (2005) In vitro metabolism of nitric oxide-donating aspirin: The effect of positional isomerism. J. Pharmacol. Exp. Ther., 312, 989-997.